Drug Profile
Research programme: neurological disorders - IBI-Lorenzini Istituto-Biochimico-Italiano-G-Lorenzini
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Istituto Biochimico Italiano G Lorenzini
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Cerebral ischaemia
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Alzheimer's-disease in Italy (Parenteral)
- 28 Oct 2020 No recent reports of development identified for research development in Cerebral-ischaemia in Italy (Parenteral)
- 16 Sep 2016 Early research in Alzheimer's disease in Italy (Parenteral) before September 2016 (IBI-Lorenzini website, September 2016)